"Real-life" results of front-line treatment with Imatinib in older patients (≥65 years) with newly diagnosed chronic myelogenous leukemia

Leukemia Research

Volumn 34, Issue 11, 2010, Pages 1472-1475

  Latagliata, Roberto ^a   Breccia, Massimo ^a   Carmosino, Ida ^a   Cannella, Laura ^a   De Cuia, Rosa ^a   Diverio, Daniela ^a   Frustaci, Anna ^a   Loglisci, Giuseppina ^a   Mancini, Marco ^a   Santopietro, Michelina ^a   Stefanizzi, Caterina ^a   Volpicelli, Paola ^a   Vozella, Federico ^a   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

CML; Comorbidity; Imatinib; Older patients; Toxicity

Indexed keywords

HEMOGLOBIN; IMATINIB; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ATTITUDE TO HEALTH; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CARDIOTOXICITY; CAUSE OF DEATH; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELDERLY CARE; EVENT FREE SURVIVAL; EYE TOXICITY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; NEUROTOXICITY; NEUTROPHIL COUNT; OVERALL SURVIVAL; PRIMARY HEALTH CARE; PRIORITY JOURNAL; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTE COUNT; TREATMENT DURATION; WORLD HEALTH ORGANIZATION; AGE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; REMISSION; TOXICITY; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION; TREATMENT OUTCOME; BENZAMIDES;

EID: 77957021650     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.07.001     Document Type: Article

References (18)

1. Helhmann R., Berger U., Hochhaus A. Chronic myeloid leukemia: a model for oncology. Ann Hematol 2005, 84:487-497.
2. Daley G.Q., Van Etten R.A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990, 247:824-830.
3. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031-1037.
4. Baccarani M., Saglio G., Goldman J., Hochhaus A., Simonsson B., Appelbaum F., et al. Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European Leukemianet. Blood 2006, 108:1809-1818.
5. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., et al. IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355(23):2408-2417.
6. Branford S., Seymour J., Grigg A., Arthur C., Rudzki Z., Lynch K., et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 2007, 13:7080-7086.
7. Hochhaus A., Druker B., Sawyers C., Guilhot F., Schiffer C.A., Cortes J., et al. Favorable long-term follow-up results over six years for response, survival and safety with imatinib mesylate therapy in chronic phase chronic myeloid leukemia post failure of interferon-alpha treatment. Blood 2008, 111:1039-1043.
8. Rohrbacher M., Berger U., Hochhaus A., Metzgeroth G., Adam K., Lahaye T., et al. Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia 2009, 23:602-604.
9. Marin D., Milojkovic D., Olavarria E., Khorashad J.S., de Lavallade H., Reid A.G., et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008, 112:4437-4444.
10. Cortes J.E., Kantarjian H.M., Goldberg S.L., Powell B.L., Giles F.J., Wetzler M., et al. High-dose Imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. J Clin Oncol 2009, 27:4754-4759.
11. Baccarani M., Rosti G., Castagnetti F., Haznedaroglu I., Porkka K., Abruzzese E., et al. Comparison of imatinib 400mg and 800mg daily in the front-line treatment of high-risk. Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood 2009, 113:4497-4504.
12. Cortes J., Talpaz M., O'Brien S., Giles F., Beth Rios M., Shan J., et al. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 2003, 98(15):1105-1113.
13. Latagliata R., Breccia M., Carmosino I., Sarlo C., Montefusco E., Mancini M., et al. Older patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment. Leuk Res 2005, 29:287-291.
14. Rosti G., Iacobucci I., Bassi S., Castagnetti F., Amabile M., Cilloni D., et al. Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. Haematologica 2007, 92:101-105.
15. Sheehy O.M., Irvine A.E., Cuthbert R.J., Humphreys M.W., McMullin M.F. Use of imatinib mesylate in older patients in Northern Ireland: evidence of comparable haematological and molecular responses to younger patients. Hematology 2008, 13:133-136.
16. Hughes T., Deininger M., Hochhaus A., Branford S., Radich J., Kaeda J., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006, 108:28-37.
17. Oken M., Creech R., Tormey D., Horton J., Davis T., McFadden E., Carbone P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:565-579.
18. Mohanram A., Zhang Z., Shahinfar S., Lyle P.A., Toto R.D. The effect of losartan on haemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes. Kidney Int 2008, 73:630-636.